Header Logo

Connection

STEPHEN HAHN to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications STEPHEN HAHN has written about Neoplasm Staging.
STEPHEN HAHN
Connection Strength
0.408
Neoplasm Staging
  1. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer. Lung Cancer. 2018 07; 121:30-36.
    View in: PubMed
    Score: 0.054
  2. Stereotactic body radiation therapy for lung cancer. Chest. 2013 Jun; 143(6):1784-1790.
    View in: PubMed
    Score: 0.039
  3. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol. 2012 Apr; 7(4):709-15.
    View in: PubMed
    Score: 0.036
  4. New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. Clin Cancer Res. 2011 Jul 01; 17(13):4192-9.
    View in: PubMed
    Score: 0.034
  5. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg. 2003 Mar; 75(3):952-9.
    View in: PubMed
    Score: 0.019
  6. Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy. Clin Cancer Res. 2020 05 15; 26(10):2372-2380.
    View in: PubMed
    Score: 0.015
  7. Early Detection of Recurrence in Patients With Locally Advanced Non-Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. Clin Lung Cancer. 2019 09; 20(5):384-390.e2.
    View in: PubMed
    Score: 0.015
  8. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. Clin Lung Cancer. 2019 01; 20(1):e63-e71.
    View in: PubMed
    Score: 0.014
  9. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
    View in: PubMed
    Score: 0.014
  10. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol. 2017 11; 125(2):325-330.
    View in: PubMed
    Score: 0.013
  11. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.013
  12. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.013
  13. Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. Ann Surg Oncol. 2017 May; 24(5):1419-1427.
    View in: PubMed
    Score: 0.012
  14. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280.
    View in: PubMed
    Score: 0.012
  15. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? Breast. 2017 Feb; 31:192-196.
    View in: PubMed
    Score: 0.012
  16. Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years. Ann Thorac Surg. 2017 Mar; 103(3):912-919.
    View in: PubMed
    Score: 0.012
  17. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 02; 12(2):281-292.
    View in: PubMed
    Score: 0.012
  18. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
    View in: PubMed
    Score: 0.012
  19. Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.011
  20. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer. 2015 Apr 01; 121(7):1118-27.
    View in: PubMed
    Score: 0.011
  21. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer. 2013 Sep 01; 119(17):3123-32.
    View in: PubMed
    Score: 0.010
  22. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012 May; 93(5):1658-65; discussion 1665-7.
    View in: PubMed
    Score: 0.009
  23. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. Radiother Oncol. 2010 May; 95(2):178-84.
    View in: PubMed
    Score: 0.008
  24. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung. 2004; 182(3):151-62.
    View in: PubMed
    Score: 0.005
  25. Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology. 1999 Dec; 213(3):845-52.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.